Compare Funko Inc (FNKO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Funko Inc trades at $5.75 (market cap $315.21M), while Vertex Pharmaceuticals Incorporated trades at $483.06 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 384.2× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| FNKO | VRTX | |
|---|---|---|
Market Cap | $315.21M | $121.09B |
Sector | Consumer Staples | Health |
52-Week High | $5.88 | $529.59 |
52-Week Low | $2.46 | $366.54 |
Enterprise Value | $560.25M | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $5.55, down 2.46% on the day, with a bullish technical signal from moving averages. The company shows mixed fundamentals with a low P/S ratio of 0.34 and strong gross margins near 40%, but negative net income and ROE. Recent quarters have seen earnings beats against expectations, and analyst sentiment leans positive with a 42.86% buy rating and no sell recommendations. News highlights new product launches and a strong Q1 2026 report.
The outlook balances product-driven revenue potential against persistent profitability challenges. Investment opportunity lies in the low valuation multiple and recent earnings momentum, but risks include sustained negative margins, high debt levels, and volatile cash flows from operations.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
